Rosemary & sage extracts inspire a potential anti-inflammatory drug for Alzheimer’s. Scripps Research created a stable form of carnosic acid, improving memory in the lab.
The new Alzheimer's antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
New research suggests antidepressants accelerate cognitive decline in dementia. Learn which drugs appear to be less harmful than others. Help your doctor make better treatment decisions.
(Video & Article) L.A.T.E. Dementia is frequently misdiagnosed as Alzheimer's. That's why, in January 2025, researchers created new guidelines. It affects millions of people, approximately 40% of people over 80. How is it recognized? What makes it different?
A new analysis of the benefits of these Alzheimer's treatments scores the days and ways patients succeed in living independently.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
Learn the latest research at Rush University on dementia-preventing activities that keep your brain refreshingly healthy.
Ambien (Zolpidem), a sleeping pill, was studied to see its effects on the brain. Learn to think twice before reaching for a sleeping pill – while you can still think clearly.
Newer blood tests accurately predict Alzheimer's. This opens the door to earlier detection and treatment. Be cautious: only taking these tests with guidance from a medical expert.
Learn about 2025's newly approved or potential Alzheimer's drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
Leqembi and Kisunla are the new Alzheimer's immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what's going on.
A trio of key studies identified predictors of dementia risk, the benefits of detecting cognitive impairment early and identified barriers to routine cognitive screening in older adults, such as cost. See their recommendations.
